Physician profile
Ruth Horowitz
NPI 1003811423
$6,980.11
in general payments reported to CMS, 2019-2025
55 companies · $1,072 in 2025
The $1,072 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,040 · 2020: $518 · 2021: $790 · 2022: $1,110 · 2023: $1,256 · 2024: $1,193 · 2025: $1,072.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,498 · Education: $24.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,497.73 |
| Education | $24.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $568.89 | 2019-2025 | Evenity, Prolia, Tepezza |
| Novo Nordisk INC | $471.82 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $424.73 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $362.96 | 2019-2025 | |
| Radius Health, INC. | $348.74 | 2020-2025 | Tymlos |
| Corcept Therapeutics | $295.89 | 2021-2025 | Korlym |
| Tandem Diabetes Care, INC. | $256.66 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbott Laboratories | $246.52 | 2019-2025 | Freestyle Libre 3 |
| Insulet Corporation | $212.48 | 2019-2025 | Omnipod |
| Bayer Healthcare Pharmaceuticals INC. | $202.99 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $195.32 | 2019-2025 | Strensiq |
| Astrazeneca Pharmaceuticals Lp | $195.26 | 2019-2023 | Farxiga |
| Mannkind Corporation | $173.98 | 2019-2024 | Afrezza |
| Lilly USA, LLC | $170.91 | 2019-2025 | Mounjaro, Zepbound |
| Cequr Corporation | $156.93 | 2023-2025 | Cequr Simplicity |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $147.70 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Novartis Pharmaceuticals Corporation | $146.58 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $137.48 | 2020-2025 | Jardiance, Tradjenta, Synjardy |
| Horizon Therapeutics Plc | $130.93 | 2020-2023 | Tepezza |
| Dexcom, INC. | $126.59 | 2019-2023 | Dexcom G6 Transmitter |
| Recordati_rare_diseases_inc. | $125.25 | 2021-2025 | Isturisa, Signifor Lar |
| Amneal Pharmaceuticals LLC | $122.91 | 2022-2025 | Unithroid |
| Lifescan, INC. | $119.73 | 2019-2022 | |
| Amarin Pharma, INC. | $119.50 | 2019-2023 | |
| Xeris Pharmaceuticals, INC. | $117.04 | 2021-2023 | Gvoke Hypopen |
| Becton, Dickinson and Company | $114.23 | 2019-2022 | |
| Beta Bionics, INC. | $113.68 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Ibsa Pharma INC. | $98.64 | 2020-2024 | Tirosint, Licart, Tirosint |
| Ascendis Pharma Endocrinology INC | $85.36 | 2023-2025 | Yorvipath |
| Nevro Corp. | $84.53 | 2022-2023 | Senza |
| Medtronic, INC. | $81.88 | 2022-2025 | Minimed 780g |
| Neurocrine Biosciences, INC. | $80.11 | 2024-2025 | |
| Embecta Corp. | $63.55 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Shire North American Group INC | $62.87 | 2019 | |
| Kyowa Kirin, INC. | $57.60 | 2023 | Crysvita |
| Janssen Pharmaceuticals, INC | $54.47 | 2019-2020 | |
| Averitas Pharma INC. | $50.39 | 2024 | Qutenza |
| Almatica Pharma LLC | $44.47 | 2024-2025 | Teriparatide |
| Medtronic Minimed, INC. | $41.03 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $39.06 | 2019 | |
| Valeritas, INC. | $32.75 | 2019 | |
| Madrigal Pharmaceuticals | $32.21 | 2025 | Rezdiffra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.34 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.21 | 2020-2021 | |
| Tolmar, INC. | $27.38 | 2023-2024 | |
| Soleno Therapeutics, INC. | $24.83 | 2025 | Vykat Xr |
| Ultragenyx Pharmaceutical INC. | $22.55 | 2023 | |
| Sequel Med Tech, LLC | $21.81 | 2025 | Twiist |
| Zealand Pharma US, INC. | $21.16 | 2021 | |
| Globus Medical, INC. | $18.57 | 2025 | Senza |
| Ascensia Diabetes Care US INC. | $16.03 | 2022 | |
| Azurity Pharmaceuticals, INC. | $14.64 | 2023 | Adthyza |
| Ge Healthcare | $13.87 | 2023 | |
| Pfizer INC. | $13.16 | 2022 | |
| Merck Sharp & Dohme LLC | $12.94 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruth Horowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.